Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for eptinezumab

  1. Eptinezumab for preventing migraine (TA871)

    Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    1 March 2023
    View recommendations

    Sections for TA871

  2. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    15 May 2024
    View recommendations

    Sections for TA973

  3. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals

  4. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    5 July 2023
    View recommendations

    Sections for TA906